{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:21:04Z","timestamp":1793409664777,"version":"4.5.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Secondary hypogammaglobulinemia, or low serum immunoglobulins, is associated with a variety of medications or medical conditions and may be symptomatic and lead to increased infectious risk. There is limited data regarding the study of acquired, or secondary, hypogammaglobulinemia (SHG) in pediatrics. The data to date has suffered from methodologic issues including retrospective study design, lack of baseline immunoglobulin measurements, and limited longitudinal follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>There is emerging research on the impact of B-cell depleting therapies, specifically rituximab and chimeric antigen T-cells, along with other autoimmune and malignant disease states, in the development of SHG in pediatric patients. This review will also summarize other relevant pediatric conditions related to SHG.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The clinical relevance of SHG in pediatrics is increasingly appreciated. Improved understanding of the specific etiologies, risk factors, and natural history of SHG have informed screening and management recommendations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001396","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T11:40:26Z","timestamp":1725968426000},"page":"659-667","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Secondary hypogammaglobulinemia: diagnosis and management of a pediatric condition of clinical importance"],"prefix":"10.1097","volume":"36","author":[{"given":"Daniel","family":"DiGiacomo","sequence":"first","affiliation":[{"name":"Department of Pediatrics, K. Hovnanian Children's Hospital, Jersey Shore University Medical Center, Neptune"},{"name":"Hackensack Meridian School of Medicine, Nutley, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Barmettler","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J Clin Immunol"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"vi50","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.clml.2023.05.008","article-title":"Recommendations for management of secondary antibody deficiency in multiple myeloma","volume":"23","author":"Giralt","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.bbmt.2017.04.026","article-title":"Recommendations for screening and management of late effects in patients with severe combined immunodeficiency after allogenic hematopoietic cell transplantation: a consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT","volume":"23","author":"Heimall","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaip.2019.07.032","article-title":"Rituximab unveils hypogammaglobulinemia and immunodeficiency in children with autoimmune cytopenia","volume":"8","author":"Ottaviano","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/eji.202149667","article-title":"Secondary rituximab-associated versus primary immunodeficiencies: the enigmatic border","volume":"52","author":"Ottaviano","year":"2022","journal-title":"Eur J Immunol"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jaci.2018.02.017","article-title":"Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood","volume":"141","author":"Blanco","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jaci.2021.03.041","article-title":"Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients","volume":"148","author":"Labrosse","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","article-title":"Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab","volume":"130","author":"Athni","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1542\/peds.2008-2361","article-title":"B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus","volume":"123","author":"Kumar","year":"2009","journal-title":"Pediatrics"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/rheumatology\/keab626","article-title":"New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases","volume":"61","author":"Ong","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s00467-023-05913-1","article-title":"Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey","volume":"38","author":"Zurowska","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00467-021-05304-4","article-title":"Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome","volume":"37","author":"Inoki","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.anai.2021.10.028","article-title":"Hypogammaglobulinemia after rituximab therapy in children","volume":"128","author":"Newman","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/archdischild-2022-324026","article-title":"Prolonged IgG recovery following rituximab administration","volume":"107","author":"Tsilifis","year":"2022","journal-title":"Arch Dis Child"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2352-3026(23)00062-5","article-title":"Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial","volume":"10","author":"Alexander","year":"2023","journal-title":"Lancet Haematol"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA Trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"R32-20250730","first-page":"1","article-title":"Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","article-title":"Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians","volume":"15","author":"Kampouri","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"R34-20250730","first-page":"S1","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transplant Infect Dis"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"e28092","DOI":"10.1002\/pbc.28092","article-title":"Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients","volume":"67","author":"Arnold","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor t-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T \u2013 and a side order of IgG, to go? \u2013 immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/tid.14109","article-title":"Vaccine schedule recommendations and updates for patients with hematologic malignancy posthematopoietic cell transplant or CAR T-cell therapy","volume":"25","author":"Reynolds","year":"2023","journal-title":"Transplant Infect Dis"},{"key":"R42-20250730","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jtct.2023.10.006","article-title":"INSPIRED symposium. Part 3: prevention and management of pediatric chimeric antigen receptor T cell-associated emergent toxicities","volume":"30","author":"McNerney","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.anai.2023.01.010","article-title":"Steroid-induced secondary immune deficiency","volume":"130","author":"Mustafa","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0022-3476(96)70035-5","article-title":"Humoral immunity in steroid-dependent children with asthma and hypogammaglobulinemia","volume":"129","author":"Lack","year":"1996","journal-title":"J Pediatr"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1007\/s00431-022-04560-2","article-title":"Mycophenolate mofetil-induced hypogammaglobulinemia and infectious disease susceptibility in pediatric patients with chronic rheumatic disorders: a monocentric retrospective study","volume":"181","author":"Barbati","year":"2022","journal-title":"Eur J Pediatr"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s10157-020-01858-z","article-title":"Profound effect of postrituximab mycophenolate mofetil administration for persistent hypogammaglobulinemia in young children with steroid-dependent nephrotic syndrome","volume":"24","author":"Fujinaga","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1055\/s-0041-1736156","article-title":"Carbamazepine-induced hematological and immunological alterations in egyptian children with idiopathic generalized seizures","volume":"11","author":"El-Shimi","year":"2021","journal-title":"J Child Sci"},{"key":"R49-20250730","first-page":"65","article-title":"Effect of antiepileptic drugs on serum immunoglobulin levels in children","volume":"110","author":"Ashrafi","year":"2010","journal-title":"Acta Neurol Belg"},{"key":"R50-20250730","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1365-2249.2003.02097.x","article-title":"Immunoglobulins in children with epilepsy: the Dutch Study of Epilepsy in Childhood","volume":"132","author":"Callenbach","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"R51-20250730","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.jaip.2023.04.018","article-title":"Inborn errors of immunity and autoimmune disease","volume":"11","author":"Gray","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R52-20250730","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1177\/0961203313507990","article-title":"Hypogammaglobulinemia in pediatric systemic lupus erythematosus","volume":"22","author":"Lim","year":"2013","journal-title":"Lupus"},{"key":"R53-20250730","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12969-015-0050-8","article-title":"Primary complement and antibody deficiencies in autoimmune rheumatologic diseases with juvenile onset: a prospective study at two centers","volume":"13","author":"Sp\u00e2rchez","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"key":"R54-20250730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamanetworkopen.2020.36321","article-title":"Association of rituximab use with adverse events in children, adolescents, and young adults","volume":"4","author":"McAtee","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R55-20250730","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1089\/jayao.2020.0060","article-title":"Hypogammaglobulinemia in adolescents and young adults with acute lymphoblastic leukemia","volume":"9","author":"Lange","year":"2020","journal-title":"J Adolesc Young Adult Oncol"},{"key":"R58-20250730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ctr.14021","article-title":"Persistent hypogammaglobulinemia in pediatric solid organ transplant recipients","volume":"34","author":"Pellett Madan","year":"2020","journal-title":"Clin Transplant"},{"key":"R59-20250730","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00467-022-05757-1","article-title":"Hypogammaglobulinemia in pediatric kidney transplant recipients","volume":"38","author":"Dimitriades","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"R60-20250730","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/bmt.2013.76","article-title":"Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT","volume":"48","author":"Frangoul","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"R61-20250730","first-page":"CD001239","article-title":"Intravenous immunoglobulin for suspected or proven infection in neonates","volume":"1","author":"Ohlsson","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R62-20250730","first-page":"CD000361","article-title":"Intravenous immunoglobulin for preventing infection in preterm and\/or low birth weight infants","volume":"1","author":"Ohlsson","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R63-20250730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/pai.13911","article-title":"Expected impact of immunomodulatory agents during pregnancy: a newborn's perspective","volume":"34","author":"Luo","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"R64-20250730","first-page":"1","article-title":"Hypogammaglobulinemia in neonates: illustrative cases and review of the literature","volume":"4","author":"Darmawan","year":"2023","journal-title":"J Perinatol"},{"key":"R66-20250730","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/08880018.2022.2049936","article-title":"Outcomes of blinatumomab based therapy in children with relapsed, persistent, or refractory acute lymphoblastic leukemia: a multicenter study focusing on predictors of response and posttreatment immunoglobulin production","volume":"39","author":"Essa","year":"2022","journal-title":"Pediatr Hematol Oncol"},{"key":"R67-20250730","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.anai.2021.08.413","article-title":"Secondary immunodeficiencies: an overview","volume":"127","author":"Tuano","year":"2021","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:04:17Z","timestamp":1753898657000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001396","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]}}}